(Q35789007)

10 August 2017

1 reference

title

Origins, practices and future of safety pharmacology (English)

1 reference

10 August 2017

1 reference

Alan Bass

1

1 reference

10 August 2017

Lewis Kinter

series ordinal

2

1 reference

10 August 2017

Patricia Williams

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 May 2004

1 reference

Journal of Pharmacological and Toxicological Methods

10 August 2017

published in

1 reference

10 August 2017

volume

49

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

145-151

1 reference

The long QT syndrome: ion channel diseases of the heart

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Determination of beta-adrenergic receptor blocking pharmaceuticals in United States wastewater effluent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Predictability of clinical adverse reactions of drugs by general pharmacology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Safety pharmacology and risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Evaluation and applications of radiotelemetry in small laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Integration of safety pharmacology endpoints into toxicology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Human subjects. Volunteer's death prompts review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Clinical research. Procedures faulted in fatal asthma trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

The application of toxicokinetic data to dosage selection in toxicology studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

The QT interval and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Assessment of respiratory function in safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

New perspectives in CNS safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Expanded clinical observations in toxicity studies: historical perspectives and contemporary issues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

Long QT syndromes and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

The role of pharmacological profiling in safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.007

10.1016/J.VASCN.2004.02.007

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference